
Lexaria nets $2.6M Australian tax rebate to fund future R&D without shareholder dilution
Lexaria Bioscience Corp. received a USD$2.6 million (AUD$3.67 million) cash rebate from the Australian Tax Office for its 2025 human study conducted in Australia. This rebate, part of the Australian R&D Tax Incentive Program, was awarded after verify...

